Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cybin Inc (CYBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: CYBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $83.31
1 Year Target Price $83.31
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.58% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 150.07M USD | Price to earnings Ratio - | 1Y Target Price 83.31 |
Price to earnings Ratio - | 1Y Target Price 83.31 | ||
Volume (30-day avg) 5 | Beta 1.06 | 52 Weeks Range 4.81 - 13.88 | Updated Date 10/14/2025 |
52 Weeks Range 4.81 - 13.88 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.25% | Return on Equity (TTM) -54.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 81432224 | Price to Sales(TTM) 278.25 |
Enterprise Value 81432224 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 25188217 | Shares Floating 19964487 |
Shares Outstanding 25188217 | Shares Floating 19964487 | ||
Percent Insiders 32.77 | Percent Institutions 38.97 |
Upturn AI SWOT
Cybin Inc
Company Overview
History and Background
Cybin Inc. is a biopharmaceutical company focused on psychedelic drug development. Founded in 2019, it aims to address mental health disorders through innovative psychedelic therapies. Key milestones include securing clinical trial approvals and advancing drug candidates through preclinical and clinical stages.
Core Business Areas
- Drug Discovery and Development: Focuses on developing novel psychedelic molecules and formulations.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Builds a portfolio of patents and intellectual property related to psychedelic therapies.
Leadership and Structure
Cybin is led by Doug Drysdale (CEO) and a team of executives with experience in pharmaceuticals and drug development. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- CYB003: A deuterated psilocybin analog being developed for the treatment of Major Depressive Disorder (MDD). Currently in clinical trials. Market share data is unavailable as the drug is not yet approved. Competitors include companies developing psilocybin-based therapies, such as COMPASS Pathways.
- CYB004: A DMT based molecule under development. Currently in clinical trials. Market share data is unavailable as the drug is not yet approved. Competitors include companies developing DMT based therapies, such as GH Research.
Market Dynamics
Industry Overview
The psychedelic medicine industry is an emerging field focused on developing therapies for mental health disorders. The market is growing rapidly, driven by increasing awareness of the potential benefits of psychedelics and changing regulatory landscapes.
Positioning
Cybin is positioned as an innovative company developing novel psychedelic molecules and formulations. Its competitive advantage lies in its focus on deuterated compounds and its intellectual property portfolio.
Total Addressable Market (TAM)
The TAM for mental health treatments is estimated to be billions of dollars. Cybin aims to capture a significant share of this market by developing effective and differentiated psychedelic therapies.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced management team
- Focus on novel psychedelic molecules
- Clinical trials underway
Weaknesses
- Early-stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Regulatory hurdles
Opportunities
- Growing market for psychedelic therapies
- Potential for breakthrough therapies
- Partnerships with pharmaceutical companies
- Expanding clinical trial programs
Threats
- Regulatory challenges
- Competition from other psychedelic companies
- Clinical trial failures
- Financing risks
Competitors and Market Share
Key Competitors
- CMPS
- GHRS
Competitive Landscape
Cybin faces competition from other psychedelic companies, but differentiates itself through its focus on novel molecules and intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D spending and expanding clinical trial programs.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing CYB003 into Phase 2 clinical trials and expanding partnerships.
Summary
Cybin is a biopharmaceutical company focused on psychedelic drug development. While it has a strong intellectual property portfolio and experienced leadership, it is an early-stage company with high cash burn and faces regulatory and clinical trial risks. Successful clinical trial results and regulatory approvals are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cybin Inc. Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cybin Inc
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | Co-Founder, Interim CEO, President & Executive Chairman Mr. Eric So L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://cybin.com |
Full time employees 50 | Website https://cybin.com | ||
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.